[HTML][HTML] Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study
Purpose Brexucabtagene autoleucel (KTE-X19) autologous anti-CD19 chimeric antigen
receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell
lymphoma (MCL). Outcomes after a 3-year follow-up in the pivotal ZUMA-2 study of KTE-X19
in relapsed/refractory MCL are reported, including for subgroups by prior therapy
(bendamustine and type of Bruton tyrosine kinase inhibitor [BTKi]) or high-risk
characteristics. Methods Patients with relapsed/refractory MCL (one to five prior therapies …
receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell
lymphoma (MCL). Outcomes after a 3-year follow-up in the pivotal ZUMA-2 study of KTE-X19
in relapsed/refractory MCL are reported, including for subgroups by prior therapy
(bendamustine and type of Bruton tyrosine kinase inhibitor [BTKi]) or high-risk
characteristics. Methods Patients with relapsed/refractory MCL (one to five prior therapies …
以上显示的是最相近的搜索结果。 查看全部搜索结果